Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587535 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2XDHKDM4EL3MBTL1MAPK1 | |
| SCHEMBL29510064 | 0.93 | KDM4E (0.50) | SMN1; SMN2XDHKDM4EL3MBTL1MAPK1 | |
| SCHEMBL4586157 | 0.86 | CTSL (0.55) | SMN1; SMN2XDHKDM4ECTSLMGLL | |
| SCHEMBL4586154 | 0.86 | CTSL (0.55) | SMN1; SMN2XDHKDM4ECTSLMGLL | |
| SCHEMBL257218 | 0.86 | CTSL (0.55) | SMN1; SMN2XDHKDM4ECTSLMGLL | |
| SCHEMBL8407033 | 0.83 | MGLL (0.58) | SMN1; SMN2XDHKDM4ECTSLMGLL | |
| SCHEMBL4586342 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2XDHKDM4EL3MBTL1CTSL | |
| SCHEMBL28487187 | 0.81 | L3MBTL1 (0.58) | SMN1; SMN2XDHKDM4EL3MBTL1MEN1 | |
| SCHEMBL4586337 | 0.81 | ALDH1A1 (0.51) | SMN1; SMN2XDHKDM4EL3MBTL1CTSL | |
| SCHEMBL13853886 | 0.81 | KDM4E (0.54) | SMN1; SMN2XDHKDM4EL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556364-A4 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ CORP (KR) | 2008-04-16 | — | — | EP | disclosed |
| US-6967213-B2 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP. (KR) | 2005-11-22 | — | — | US | disclosed |
| EP-1556364-A1 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ Corp. (KR) | 2005-07-27 | — | — | EP | disclosed |
| EP-1528059-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle LLC (US) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004035553-A1 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ CORP. (KR) | 2004-04-29 | — | — | WO | disclosed |
| US-20040072884-A1 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP. (KR) | 2004-04-15 | — | — | US | disclosed |
| EP-0809636-B1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1223167-A2 | Substituted isoxazoles for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-5859257-A | ANTIINFLAMMATORY, ANTIARTHRITIC AGENTS | G. D. SEARLE & CO. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0809636-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025405-A1 | SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072884-A1 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CYP3A5, CYP2C9, CYP2C19 | SMN1; SMN2 3366/4885XDH 2015/4885KDM4E 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.